^
    1d
    68Ga-pentixafor PET/CT shows better diagnostic performance than 18F-FDG PET/CT in chronic lymphocytic leukemia/small lymphocytic lymphoma: a case report and review of literature. (PubMed, Front Oncol)
    Compared with 18F-FDG, 68Ga-pentixafor PET/CT detected more lesions with significantly higher tracer uptake. This case suggests that, for patients with CLL/SLL, 68Ga-pentixafor PET/CT demonstrates significantly superior performance in evaluating the tumor burden and delineating the disease extent compared with 18F-FDG PET/CT.
    Journal
    |
    CD20 (Membrane Spanning 4-Domains A1) • CCND1 (Cyclin D1) • BCL6 (B-cell CLL/lymphoma 6) • CD5 (CD5 Molecule) • MME (Membrane Metalloendopeptidase) • SOX11 (SRY-Box Transcription Factor 11) • FCER2 (Fc Fragment Of IgE Receptor II)
    |
    CD20 positive
    1d
    Immune receptor translocation-associated protein 1 and myeloid nuclear differentiation antigen are useful markers for the differential diagnosis of marginal zone lymphoma. (PubMed, Pathology)
    Expression of IRTA1 alone, or either IRTA1+ or MNDA+, was less frequent among MZL with plasma cell differentiation than among MZL with classical cell morphology (p=0.063 and 0.071, respectively), albeit not significantly. IRTA1 and MNDA are sensitive and specific markers for the differential diagnosis of MZL, and they may be helpful in distinguishing MZL from histologic mimics.
    Journal
    |
    CCND1 (Cyclin D1) • BCL6 (B-cell CLL/lymphoma 6) • CD5 (CD5 Molecule) • MME (Membrane Metalloendopeptidase) • SOX11 (SRY-Box Transcription Factor 11) • FCER2 (Fc Fragment Of IgE Receptor II)
    1d
    Development and validation of a fluorescence polarization-based assay for USP7: From probe design to inhibitor evaluation. (PubMed, Eur J Med Chem)
    Ultimately, in vitro cellular assays identified three compounds (LC-U7-44, LC-U7-48, and LC-U7-50) that exhibit potent USP7 inhibitory activity alongside favorable cellular anti-proliferative effects. Overall, the established FP assay in this study closes a methodological gap in the evaluation of USP7 inhibitors, and the detailed SAR analysis provides a foundation for the further development of potent USP7 inhibitors.
    Journal
    |
    USP7 (Ubiquitin Specific Peptidase 7)
    3d
    Therapy-driven clonal dynamics in chronic lymphocytic leukemia. (PubMed, Semin Cancer Biol)
    Finally, we highlight the need for future studies addressing resistance in evolving clinical contexts, such as combination targeted therapies, bispecific antibodies, and CAR T-cell therapy. Taken together, a deeper understanding of clonal evolution is central to the development of personalized therapeutic strategies and to improving long-term outcomes for patients with CLL.
    Review • Journal • IO biomarker
    |
    TP53 (Tumor protein P53) • PLCG2 (Phospholipase C Gamma 2)
    5d
    A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (clinicaltrials.gov)
    P4, N=150, Recruiting, Eli Lilly and Company | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Zydelig (idelalisib) • Jaypirca (pirtobrutinib)
    5d
    Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood Cancers (clinicaltrials.gov)
    P2, N=13, Active, not recruiting, Eli Lilly and Company | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Jaypirca (pirtobrutinib)
    5d
    BGB-16673-102: Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader (clinicaltrials.gov)
    P1/2, N=146, Recruiting, BeiGene | Trial completion date: Sep 2027 --> Jan 2029 | Trial primary completion date: Feb 2026 --> Jan 2029
    Trial completion date • Trial primary completion date
    |
    catadegbrutinib (BGB-16673)
    6d
    MB-CART19.1 r/r CD19+ B-cell Malignancies (BCM) (clinicaltrials.gov)
    P1, N=48, Active, not recruiting, Miltenyi Biomedicine GmbH | Trial completion date: Mar 2026 --> Jun 2026 | Trial primary completion date: Mar 2026 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    CD19 (CD19 Molecule)
    |
    zorpocabtagene autoleucel (MB-CART 19.1)
    7d
    A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring (clinicaltrials.gov)
    P1, N=52, Enrolling by invitation, Janssen Research & Development, LLC | N=35 --> 52
    Enrollment change
    |
    Imbruvica (ibrutinib) • safimaltib (JNJ-6633) • JNJ-4681 • JNJ-6665 • JNJ-8543 • JNJ-8902 • onametostat (JNJ-64619178) • rezetamig (JNJ-8780)
    7d
    BGB-11417-303: A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL) (clinicaltrials.gov)
    P3, N=630, Recruiting, BeOne Medicines
    Trial initiation date
    |
    Venclexta (venetoclax) • Rituxan (rituximab) • Gazyva (obinutuzumab) • sonrotoclax (BGB-11417)
    7d
    The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies (clinicaltrials.gov)
    P1/2, N=144, Recruiting, AVM Biotechnology Inc | Trial completion date: Dec 2026 --> Dec 2028 | Trial primary completion date: Apr 2026 --> Nov 2027
    Trial completion date • Trial primary completion date
    |
    TP53 mutation • TP53 mutation + Chr del(17p)
    |
    dexamethasone sodium phosphate (AVM0703)
    7d
    Factors influencing front line treatment of chronic lymphocytic leukemia: A French real-world study. (PubMed, Cancer)
    This study is the first to report real-world evidence on treatment choice in first-line CLL and highlight two distinct groups of patients.
    Journal • Real-world evidence
    |
    TP53 (Tumor protein P53) • IGH (Immunoglobulin Heavy Locus)
    |
    TP53 mutation
    |
    Venclexta (venetoclax) • Gazyva (obinutuzumab) • Brukinsa (zanubrutinib) • Calquence (acalabrutinib)